Ascletis Pharma Announces Positive Phase II Results for ASC30 in Obesity Treatment
Ascletis Pharma Announces Positive Phase II Results for ASC30 in Obesity Treatment
Key Highlights from the Report
- Successful Phase II Results: Ascletis Pharma Inc. has announced positive topline results from its U.S. Phase II, 24-week study evaluating its ultra-long-acting subcutaneous (SQ) depot formulation of the small molecule GLP-1R agonist ASC30 for obesity.
- Significant Weight Loss Achieved: The ASC30 SQ depot formulation achieved a statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after only three monthly doses.
- Maintenance of Weight Loss: The drug maintained weight loss for four months following the third and final monthly dose, suggesting the potential for quarterly dosing as a maintenance therapy.
- Safety Profile: ASC30 exhibited a safety and tolerability profile consistent with the GLP-1 drug class, with all adverse events (AEs) being mild to moderate and no discontinuations due to AEs.
- Novel Dosing Regimen: ASC30 SQ depot formulation is the first GLP-1 agonist to deliver class-consistent weight loss with once-monthly injection, without the need for lead-in weekly injections, and to maintain weight loss up to four months after the last dose.
- Patent Protection: ASC30 is a new chemical entity (NCE) with U.S. and global patent protection through 2044 (excluding extensions).
Detailed Study Results
- The Phase II study was a randomized, double-blind, placebo-controlled, and multi-center trial conducted in the U.S. with 65 participants who were obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 but < 30 kg/m2) and had at least one weight-related comorbidity.
- Participants received three monthly doses of ASC30 SQ depot (400 mg each for formulation A1) or matching placebo at Day 1, Day 29 (Week 4), and Day 57 (Week 8), with no requirement for lead-in weekly doses.
- The primary endpoint was met: patients receiving ASC30 A1 had a statistically significant placebo-adjusted mean weight loss of 6.3% at week 12 and 7.5% at week 16.
- Duration of Effect: Weight loss was maintained during the 16-week maintenance period post-final dose, with placebo-adjusted mean weight loss of 6.4% at week 20 and 5.8% at week 24, supporting the potential for once-quarterly maintenance therapy.
- Pharmacokinetics: ASC30 A1 demonstrated an observed half-life of 46 to 75 days in previous studies, supporting its ultra-long-acting profile.
- Safety: No discontinuations due to adverse events, all AEs were mild to moderate, all gastrointestinal AEs were mild, and no hepatic safety signals or abnormal lab findings were reported.
- Formulation A2: Did not achieve therapeutic drug exposures in this study and had no prior human data.
Management Commentary
Dr. Jinzi Jason Wu, Founder, Chairman, and CEO of Ascletis, highlighted that ASC30 is the first and only incretin to demonstrate effective weight loss with once-daily oral dosing, once-monthly SQ dosing for treatment, and once-quarterly SQ dosing for maintenance in two Phase II studies for obesity. He noted that the competitive efficacy and well-tolerated safety profile of ASC30 strengthen their confidence in expanding the clinical development program. The results validate Ascletis’ proprietary Ultra-Long-Acting Platform (ULAP) technology for developing once-monthly to once-quarterly therapies for chronic weight management.
Implications for Shareholders and Potential Share Price Impact
- Significant Market Opportunity: The ability to offer a once-monthly or once-quarterly injectable GLP-1 therapy for obesity with proven efficacy and safety represents a substantial commercial opportunity, potentially positioning Ascletis as a major competitor in the growing obesity therapeutics market.
- First-in-Class Dosing Regimen: The achievement of class-consistent weight loss without the need for weekly lead-in injections is a major competitive differentiator, likely to increase patient compliance and market uptake.
- Patent Protection: Long-term patent protection until 2044 provides a robust barrier to competition, enhancing the potential value of ASC30 to shareholders.
- Positive Clinical Data: These results may drive increased investor confidence and could be seen as a price-sensitive development with the potential to move Ascletis’ share price.
- Expansion Potential: The company’s stated intention to expand the clinical development program for both treatment and maintenance dosing regimens highlights further growth prospects.
- Caution: The company notes that there is no guarantee of ultimate successful development, manufacturing, or commercialization of ASC30.
About ASC30
ASC30 is a proprietary, investigational, small molecule GLP-1R biased agonist designed for both oral (once daily) and subcutaneous (once monthly to once quarterly) administration. It is protected by U.S. and global patents through 2044, excluding potential extensions. ASC30 was discovered and developed in-house at Ascletis, underscoring the company’s innovation capabilities.
Board and Leadership
The announcement was made under the authority of Dr. Jinzi Jason Wu, Chairman. Other board members include Mrs. Judy Hejingdao Wu (Executive Director), Dr. Yizhen Wei, Mr. Jiong Gu, and Ms. Lin Hua (Independent Non-Executive Directors).
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The clinical development process is subject to significant risks and uncertainties, and there is no assurance of regulatory approval or commercial success. Investors should exercise caution and consult with professional advisors before making investment decisions.
View ASCLETIS-B Historical chart here
